Eledon Pharmaceuticals (ELDN)
(Delayed Data from NSDQ)
$2.64 USD
+0.04 (1.54%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $2.64 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.64 USD
+0.04 (1.54%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $2.64 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Zacks News
Are Medical Stocks Lagging DaVita (DVA) This Year?
by Zacks Equity Research
Here is how DaVita HealthCare (DVA) and Eledon Pharmaceuticals, Inc. (ELDN) have performed compared to their sector so far this year.
Eledon Pharmaceuticals (ELDN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Eledon Pharmaceuticals (ELDN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Eledon Pharmaceuticals, Inc. (ELDN) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Eledon Pharmaceuticals, Inc. (ELDN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Eledon Pharmaceuticals (ELDN) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Eledon Pharmaceuticals (ELDN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Eledon Pharmaceuticals, Inc. (ELDN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
Eledon Pharmaceuticals, Inc. (ELDN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Moving Average Crossover Alert: Eledon Pharma (ELDN)
by Zacks Equity Research
Eledon Pharmaceuticals (ELDN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.